Fig. 2From: Genetic risk for atrial fibrillation could motivate patient adherence to warfarin therapy: a cost effectiveness analysisAdherence to warfarin therapy among test-positive patients and cost/QALY. The cost-effectiveness of genetic testing (ICER in US dollars) as a function of the initial rate of adherance to warfarin among test positive patients who initially decline warfarin therapyBack to article page